Pimozide: EEG Effects Related to Clinical Response *

Brasseur R. : “Essais cliniques du pimozide dans le traitement des psychoses chroniques.” In Warot P. (Ed.), Compte Rendu du Congres de Psychiatrie et de Neurologie de Langue Française, LXVIIe Session. Paris, Masson et Cie, 1970.

Brugmans J. : A multicentric clinical evaluation of pimozide. Act. Neurol. Psychiat. Belg. 68: 875–887, 1968.

Janssen P. A. J. , Soudijn W. , Van Wijngaarden I. , and Dresse A. : Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. Arzneimittelforschung, 18: 274–287, 1968.

Marjerrison G. , Boulton A. A. , and Rajput A. H. : Dopa therapy in Parkinsonism: effects on the EEG and amine metabolism. Int. Z. Klin. Pharmacol. Ther. Toxik 4: 263–266, 1971.

Marjerrison G. , and Keogh R. P. : The neurophysiology of schizophrenia: field dependency and EEG responses to perceptual deprivation. J. Nerv. Ment. Dis. 152: 390–395, 1971.

Marjerrison G. , Krause A. E. , and Keogh R. P. : Variability of the EEG in schizophrenia: Quantitative analysis with a modulus voltage integrator. Electroenceph. Clin. Neurophysiol. 24: 35–41, 1968.

Sterkmans P. , Brugmans J. , and Gevers F. The clinical efficacy of pimozide in chronic psychotic patients. Clin. Trials J. 5: 1107–1112, 1968.

Sugerman A. A. , Goldstein L. , Murphree H. B. , Pfeiffer C. C. , and Jenney E. H. : EEG and behavioural changes in schizophrenia. Arch. Gen. Psychiat. 10: 340–344, 1964.